Gain Therapeutics (GANX) EBT (2020 - 2026)

Gain Therapeutics has reported EBT for 7 years, with the latest figure at -$4.6 million in Q2 2026.

• On a quarterly basis, EBT rose 19.34% year-over-year to -$4.6 million in Q2 2026; TTM through Jun 2026 was -$22.4 million, a 9.95% decrease from a year earlier, with the FY2025 full-year figure at -$22.5 million, changed 0.39% from the prior year.
• EBT was -$4.6 million for Q2 2026 at Gain Therapeutics, up from -$5.4 million in the prior quarter.
• The five-year high for EBT was -$3.3 million in Q1 2022, with the low at -$8.1 million in Q2 2024.
• Average EBT over 5 years is -$5.3 million, with a median of -$4.9 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: EBT tumbled 56.55% in 2023, then jumped 30.39% in 2025.
• Over 5 years, EBT stood at -$4.6 million in 2022, then slipped by 8.76% to -$5.0 million in 2023, then decreased by 15.59% to -$5.8 million in 2024, then sank by 32.29% to -$7.6 million in 2025, then soared by 40.19% to -$4.6 million in 2026.
• The last three EBT figures came in at -$4.6 million (Q2 2026), -$5.4 million (Q1 2026), and -$7.6 million (Q4 2025), per Business Quant data.